Dianthus Therapeutics (DNTH) Other Operating Expenses (2023 - 2024)
Dianthus Therapeutics (DNTH) posted quarterly Other Operating Expenses of -$4.8 million for Q4 2024, down 150.0% quarter-over-quarter from -$1.9 million in Q2 2023.
Dianthus Therapeutics (DNTH) Other Operating Expenses (2023 - 2024) Analysis & Trends
Dianthus Therapeutics' Other Operating Expenses history runs 2 years deep, the most recent figure standing at -$4.8 million for Q4 2024.
- In Q4 2024, Other Operating Expenses changed N/A year-over-year to -$4.8 million; the TTM figure through Sep 2025 stood at -$4.8 million (changed N/A YoY), while the FY2024 annual figure was -$4.8 million, changed N/A from the prior year.
- Other Operating Expenses for Q4 2024 stood at -$4.8 million, down from -$1.9 million in the prior quarter.
- The five-year high for Other Operating Expenses was -$1.9 million in Q2 2023, with the low at -$18.0 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -4.80 Mn |
| Jun 30, 2023 | -1.92 Mn |
| Mar 31, 2023 | -18.00 Mn |